Survodutide Side Effects: GI Rates, Risk Data & Phase 2 Trial Evidence

Overview

Survodutide (BI 456906) is Boehringer Ingelheim and Zealand Pharma's investigational dual glucagon/GLP-1 receptor agonist currently in Phase 3 trials for obesity and metabolic dysfunction-associated steatohepatitis (MASH). Unlike pure GLP-1 agonists such as semaglutide, survodutide simultaneously activates glucagon receptors — adding a metabolic dimension that improves liver fat oxidation and increases energy expenditure, but also introduces side effect considerations unique to glucagon receptor activation. The Phase 2 obesity trial (PMID 37840093, published 2023) and the Phase 2 MASH trial (PMID 38653741, published 2024) provide the most detailed safety data currently available. This article summarizes those findings systematically, with specific attention to what makes survodutide's side effect profile different from semaglutide and tirzepatide — the two closest comparators.

Gastrointestinal Side Effects: Rates and Timeline

Gastrointestinal adverse events were the most frequently reported side effects in both Phase 2 trials. In the obesity trial, nausea was reported in approximately 45–62% of participants in the highest dose cohorts (4.8 mg and 6.0 mg), with lower rates — around 28–35% — in the 2.4 mg group. Vomiting occurred in approximately 20–30% of participants at higher doses, while diarrhea affected roughly 25–35%. Decreased appetite was simultaneously a therapeutic effect and an adverse event, reported in 40–55% of participants across dose groups. Critically, GI side effects followed a predictable temporal pattern: they were most intense during the dose escalation period (weeks 1–20) and substantially diminished once participants reached their maintenance dose. In the MASH trial, a similar pattern was observed, with nausea rates peaking during the first 12 weeks and declining at stable maintenance dosing. This titration-dependent pattern is consistent with the broader GLP-1 receptor agonist class.

Dose-Dependent Side Effect Profile

Survodutide was tested at three primary maintenance doses in Phase 2: 2.4 mg, 4.8 mg, and 6.0 mg weekly. Side effect rates showed a clear dose-response relationship across all GI categories.

• 2.4 mg/week: Nausea ~28%, vomiting ~12%, diarrhea ~20% — most tolerable dose tier, lowest weight loss (~10–12%)
• 4.8 mg/week: Nausea ~45%, vomiting ~22%, diarrhea ~28% — intermediate efficacy and tolerability balance
• 6.0 mg/week: Nausea ~60%, vomiting ~30%, diarrhea ~35% — highest weight loss (~18.7%) but highest GI burden
• Discontinuation due to adverse events: approximately 8% in the 4.8 mg group and 10–12% in the 6.0 mg group, compared to ~3% in placebo
• Most GI events were rated mild to moderate in severity; severe events were uncommon (<5% across all dose groups)

Glucagon-Specific Side Effects: What Makes Survodutide Different

Unlike semaglutide (GLP-1 only) or tirzepatide (GLP-1/GIP), survodutide activates glucagon receptors — a mechanism that adds distinct physiological effects beyond appetite suppression. Glucagon receptor activation is responsible for two side effect categories not seen with pure GLP-1 agonists: **Heart rate elevation:** Glucagon increases cardiac output and heart rate. In Phase 2 trials, survodutide participants showed mean increases in resting heart rate of approximately 4–8 beats per minute, somewhat higher than the 2–4 bpm typically seen with semaglutide. This elevation was generally transient and not associated with clinical cardiac events in Phase 2 populations, but warrants monitoring in patients with pre-existing cardiac conditions. **Transient hyperglycemia during early titration:** Pure glucagon is glycemic — it stimulates hepatic glucose release. During early titration before the GLP-1 component is fully engaged, some participants in Phase 2 experienced mild, transient blood glucose elevations. In practice, the GLP-1 component sufficiently counterbalances this effect at therapeutic doses, and survodutide improved HbA1c in T2D patients. However, close monitoring during the first weeks of titration is prudent, particularly in patients with diabetes already using insulin or sulfonylureas.

Comparison to Semaglutide Side Effects

Direct cross-trial comparison is inherently limited, but the available Phase 2 data suggest that survodutide's GI side effect rates at equivalent efficacy doses are broadly similar to — and possibly slightly higher than — those of semaglutide at its weight-loss dose (2.4 mg Wegovy).

• Semaglutide (Wegovy, STEP-1): Nausea 44%, diarrhea 30%, vomiting 24%, constipation 24%
• Survodutide 4.8 mg: Nausea ~45%, diarrhea ~28%, vomiting ~22% — broadly comparable to semaglutide
• Survodutide 6.0 mg: Nausea ~60%, diarrhea ~35%, vomiting ~30% — higher GI burden for an additional ~2–4% weight loss
• Key difference: survodutide adds heart rate elevation and early-titration glucose variability (glucagon effects) absent in semaglutide
• Key advantage of survodutide: dramatic liver fat reduction (glucagon-mediated) not achievable with GLP-1 alone
• Semaglutide has SELECT cardiovascular outcomes data; survodutide has no completed CVOT yet

Liver and Hepatic Safety

The glucagon receptor activation in survodutide drives significant liver fat mobilization — precisely the mechanism responsible for its efficacy in MASH. From a safety standpoint, this hepatic activity needs to be distinguished from hepatotoxicity. In Phase 2 MASH trials, survodutide produced favorable liver enzyme trends: ALT and AST levels decreased in treated participants, consistent with resolution of hepatic inflammation. No hepatotoxicity signals were identified in either Phase 2 study. However, the degree of glucagon-driven liver fat mobilization could theoretically cause transient elevations in circulating free fatty acids or affect hepatic gluconeogenesis in susceptible individuals. Phase 3 trials include detailed hepatic monitoring protocols to capture any rare signals not detectable in smaller Phase 2 cohorts. Individuals with advanced cirrhosis were excluded from Phase 2 studies — the safety profile in this population is currently unknown.

Strategies to Minimize Side Effects

Based on the Phase 2 titration protocol and established experience with the GLP-1 agonist class, the following approaches are most effective at reducing survodutide's GI burden during titration:

• Follow the clinical trial titration schedule: start at 0.3 mg weekly and escalate every 4 weeks — rushing titration substantially increases nausea and vomiting risk
• Administer the injection on the same day each week to maintain stable drug plasma levels
• Eat smaller, more frequent meals; avoid large, fatty, or high-calorie meals which amplify GI discomfort
• Stay hydrated throughout the day, especially if diarrhea or vomiting occurs
• Avoid lying down within 2–3 hours of eating to minimize nausea and reflux symptoms
• Anti-nausea medications (e.g., ondansetron, metoclopramide) may be considered during the escalation phase under physician guidance
• If GI side effects are severe at a given dose level, extending the time at that dose before escalating (delayed titration) is preferable to discontinuation
• Monitor blood glucose more frequently during the first 4–8 weeks, particularly if using concomitant diabetes medications

Serious and Rare Adverse Events

As an investigational GLP-1 receptor agonist, survodutide carries the same class-wide precautionary concerns as semaglutide and tirzepatide. None of the following were confirmed safety signals in the Phase 2 data, but they remain important considerations for Phase 3 monitoring and eventual prescribing decisions:

• Pancreatitis — Class-wide precaution for all GLP-1 agonists. No confirmed pancreatitis cases in survodutide Phase 2 trials. Patients with a history of pancreatitis were excluded from enrollment. Severe, persistent abdominal pain should prompt immediate evaluation.
• Medullary thyroid carcinoma (MTC) — GLP-1 agonists carry a boxed warning based on thyroid C-cell tumor findings in rodent studies. No human MTC cases were identified in Phase 2. Survodutide is expected to carry this class-wide warning if approved.
• Gallbladder events — Rapid weight loss increases gallstone risk. GLP-1 agonists as a class have been associated with cholecystitis and gallstones. The 19% weight loss magnitude with survodutide may carry elevated gallbladder risk.
• Hypoglycemia — Monotherapy risk is low. However, when combined with insulin or sulfonylureas in T2D patients, dose adjustment of concomitant glucose-lowering agents may be necessary, particularly during survodutide titration.
• Cardiovascular events — Phase 2 data showed no MACE signals. Phase 3 will include cardiovascular outcome monitoring in high-risk patient subgroups.

References

1. Survodutide, a dual glucagon/GLP-1 receptor agonist, for people with overweight or obesity: a randomised, double-blind, placebo-controlled, phase 2 trial (2023) — PubMed
2. Efficacy and safety of survodutide in patients with NASH/MASH: a phase 2, randomised, double-blind, placebo-controlled trial (2024) — PubMed
3. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial) (2021) — PubMed
4. BI 456906: a novel glucagon/GLP-1 receptor co-agonist — pharmacological characterization and first-in-human data (2022) — PubMed
5. Glucagon receptor agonism in the treatment of metabolic diseases including NAFLD/NASH (2022) — PubMed